Vascular Stents Market By Product Type (Coronary Artery Stents, {Bare Metal Stents, Bioresorbable Stents, Covered Stents, Drug Eluting Stents} Peripheral Vascular Stents, {Fem-Pop Artery Stents, Iliac Artery Stents, Infrapopliteal Artery} Neurovascular Stents), By Material (Metal Stents {Stainless Steel, Cobalt-Chromium Alloys, Nitinol} Polymer Stents {Bioabsorbable Polymers, Non-biodegradable Polymers} Others), By Delivery Method (Balloon Expandable Stents, Self-Expanding Stents), By End Users (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Vascular Stents market accounted for USD 11.3 Billion in 2024 and is expected to reach USD 23.5 Billion by 2035, growing at a CAGR of around 6.9% between 2025 and 2035. The vascular stents market is a significant part of the medical devices industry in terms of the development and distribution of stents used in vascular treatments. Mesh tubes in just a few millimeters wide can be placed inside blood vessels to keep them open. Mainly, they are used for medical procedures like angioplasty to reopen narrowed or blocked arteries. It comes in three flavors bare metal, drug-eluting, and bioabsorbable. Factors driving market growth include the rising incidence of cardiovascular disease, the emergence of stent technology advancement, and demographic shifts due to age. However, complications like stent thrombosis and regulatory issues are major draws for the market. Innovations and an increased demand for healthcare services will further expand the vascular stents market.

Report Scope:

Market Dynamics

Growing Demand for Vascular Stents Due to Rising Cardiovascular Diseases

The main growth driver for vascular stents is the increasingly high incidence of cardiovascular diseases, which worldwide is one of the most common causes of death, with roughly 17.9 million deaths annually, according to WHO reports. Other factors of a graying population greatly contribute to the number of CVDs, with many more than 65%. Lifestyle factors such as sedentary lifestyles and increased obesity levels have also widened the gap, as the CDC reports that almost 40% of adults in the United States are obese.

Technology through stent design, especially drug-eluting stents, has greatly impacted patient outcomes, making this more desirable. Increased awareness of cardiovascular health, as well as advanced healthcare infrastructure, further encourage the demand for stenting procedures. Overall, the critical requirement for effective interventions amid the rising CVD rates underscores the growing importance of vascular stents in modern medicine.

Rising Awareness of Vascular Health Fuels Demand for Timely Interventions

Awareness of the health of vascular wellbeing and appropriate intervention in times like vascular stenting has accounted for the largest driver of demand to date. Public health campaigns, and education programs, on cardiovascular health indicate that more people are discovering their risk factors which include hypertension and high cholesterol. The CDC estimates that nearly half of all American adults have hypertension, which puts them at high risk of developing cardiovascular diseases. With an increase in sensibility, people visit regularly for check-ups and tests, thus, vascular diseases are detected early.

According to a study published in the Journal of the American College of Cardiology, if intervention occurs before complications set in, there is already a 40% decrease in severity. According to the American Heart Association, improved education and patient awareness show improvement through better follow-up treatment and results. As more people concentrate on optimizing vascular health, a growing demand for timely interventions, such as stenting, is expected to develop and represents an important place for education in modern healthcare.

High Costs of Advanced Stent Systems Limit Accessibility

High-priced advanced stent systems are one of the main constraints to access and uptake in health service delivery. While innovations like drug-eluting and bioabsorbable stents have many benefits, the cost of each is estimated to range from $1,000 to $3,000, driving an overall procedure cost between a likely average of $11,000 to $41,000 or higher. Such costs are a massive cost burden for many patients and healthcare systems in regions with limited coverage through insurance schemes, said the American College of Cardiology. Most of these expenses cause delayed procedures or choose fewer effective treatments. The World Health Organization also raised the fact that in low- and middle-income countries, access to essential cardiovascular care is limited by the high cost associated with advanced stenting technologies. Therefore, even though these devices provide the benefits of clinical efficiency, access to vascular interventions is not facilitated because most patients are constrained by significant fiscal limitations.

Innovations in Stent Materials to Enhance Performance and Reduce Complications

Innovations in stent materials provide great opportunities for improvements in performance and reduction of complications of vascular interventions. The recent development of bioabsorbable stents, which dissolve over time, minimizes the risks of long-term complications such as restenosis and stent thrombosis. Research published in The Lancet showed encouraging results for bioabsorbable stents because the use of these stents has resulted in a decrease in the incidence of restenosis by up to 25% compared to regular metal stents. There are new materials including cobalt-chromium alloys and polymer coatings-to be used that increase flexibility and biocompatibility and have a beneficial impact on patients.

The significant reduction of 40% in major adverse cardiac events due to innovations in stent technology over the last decade has been emphasized by the American College of Cardiology. Further research on safer and more effective stent material is sure to open the path for several eventualities that are likely to mark outstanding improvements in patient care along with outcomes in cardiovascular interventions, it would once again point out the necessity for continuous innovation in this field.

Expansion Opportunities in Neurovascular and Renal Markets for Vascular Treatments

The expansion of vascular treatments into the neurovascular and renal markets presents a significant opportunity for growth and innovation. There is a rising incidence of neurovascular diseases, such as stroke and aneurysms, thus creating a high demand for effective treatment options. World Health Organization claims that stroke is amongst the leading causes of disability and death across the world. Therefore, advanced intervention in the form of endovascular procedures and stenting calls for urgent attention. Improved catheter-based technologies and stent designs are making such treatments safer and more effective, which is why they're increasingly becoming popular in the eyes of healthcare providers and patients.

Although conditions like CKD and renal artery stenosis are on the rise in the renal market, CDC data found that approximately 15% of US adults have CKD. Advancements in stenting technologies are sure to be seen with applications such as the drug-eluting stent in renal procedures, which will improve patient outcomes who suffer from kidney malfunctioning associated with vascular impairment. The emphasis on minimally invasive techniques appears to promote individual choices to reduce recovery time and complications. These possibilities can be seen to convert into new products and therapies for customers of these markets, provide better results for patients, and expand availability of needed vascular interventions in the future.

Industry Experts Opinion

"At Abbott, we've recognized the significant burden of disease and limited treatment options available for people living with the most severe form of PAD. That's why we're revolutionizing treatments with resorbable scaffold technology below the knee," 

• Julie Tyler, senior vice president of Abbott's vascular business.

"The new Onyx Frontier DES, with its enhanced deliverability, will continue to help interventional cardiologists treat complex coronary cases and larger ranges of vessel sizes more efficiently,"

• Azeem Latib, M.D., section head of interventional cardiology

Segment Analysis

Based on the product type, the vascular stents market finds segmentation into several key areas, including Coronary Artery Stents, Bare Metal Stents, Bioresorbable Stents, Covered Stents, and Drug Eluting Stents. The market also features Peripheral Vascular Stents, which include Fem-Pop Artery Stents, Iliac Artery Stents, and Infrapopliteal Artery Stents. Neurovascular Stents also represent an important segment, especially one designed to meet the various demands arising with neurovascular conditions.

The various key segments of the vascular stents market based on the material are Metal Stents, consisting of Stainless Steel, Cobalt-Chromium Alloys, and Nitinol, Polymer Stents, which are further segmented into Bioabsorbable Polymers and Non-biodegradable Polymers, and other material.

Regional Analysis

In North America, the vascular stents market is developed due to advanced healthcare infrastructure, high patient awareness, and rising focus on innovation. The Centers for Disease Control and Prevention (CDC) report has considered heart disease as the leading cause of death in the U.S. Moreover, the presence of some major manufacturers and solid research and development activities in the region may result in the rapid introduction of new stent technologies. As a result, regulatory agencies like the FDA ensure these devices are safe and effective, accelerating the market growth. Moreover, the growing acceptance of minimally invasive procedures and advancements in stent material are changing this landscape, and North America is becoming a prime location for vascular stent innovation.

The vascular stents market is growing rapidly in the Asia Pacific region, mainly due to a significant rise in the prevalence rate of cardiovascular disease and an increase in expenditure on healthcare. Countries like China and India have dominated this market, largely because of the vast population and increased consciousness about vascular health. There is a greater demand for advanced vascular interventions in a country where cardiovascular diseases account for nearly 40% of all deaths, according to the World Health Organization, with new improved stent products making treatment more accessible and comprehensive. This region also provides minimally invasive procedure options, driven by consumer preference for faster turnaround times and fewer complications. Of late, government initiatives to gain better healthcare access and facilitate more affordable healthcare have fueled the market with extensive investment in the healthcare infrastructure of most countries. 

Competitive Landscape

Key players in the vascular stents market include Medtronic Plc, a world leader in innovation, with a wide product line comprising several types of stents, such as drug-eluting stents. It operates in more than 150 countries, and its major R&D efforts lead to continuous inventions that improve patient outcomes through advanced products approved by the FDA. Abbott Laboratories is competing with its XIENCE drug eluting stent system and recently formed alliances to begin building next-generation cardiovascular interventions. Boston Scientific Corporation also developed the Eluvia drug-eluting stent and acquired other companies to enrich its vascular portfolio. Biotronik Se & Co. Kg was committed to bioabsorbable stents and collaborated with academic centers to bring more knowledge to clinical achievement.

Vascular Stents Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In May 2024, Abbott Laboratories launched the XIENCE Sierra Everolimus Drug-Eluting Coronary Stent System in India. As one of the latest generation stents in the XIENCE family, the XIENCE Sierra is specifically designed for patients with blocked coronary arteries.
• In April 2024, Abbott Laboratories declared that the US FDA had approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), marking a breakthrough innovation for individuals with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK).
• In May 2022, Medtronic plc announced that it had received the US FDA approval for the Onyx Frontier drug-eluting stent (DES).

Report Coverage:

By Product Type

• Coronary Artery Stents
  • Bare Metal Stents
  • Bioresorbable Stents
  • Covered Stents
  • Drug Eluting Stents
• Peripheral Vascular Stents
  • Fem-Pop Artery Stents
  • Iliac Artery Stents
  • Infrapopliteal Artery

By Material

• Metal Stents
  • Stainless Steel
  • Cobalt-Chromium Alloys
  • Nitinol
• Polymer Stents
  • Bioabsorbable Polymers
  • Non-biodegradable Polymers
• Others

By Delivery Method

• Balloon Expandable Stents
• Self-Expanding Stents

By End Users

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic Plc
• Abbott Laboratories
• Boston Scientific Corporation
• Biotronik Se & Co. Kg
• Braun Melsungen Ag
• Terumo Corporation
• Microport Scientific Corporation
• Meril Life Sciences Pvt. Ltd.
• Vascular Concepts Limited
• C.R. Bard, Inc.
• W.L. Gore and Associates, Inc.
• Endologix, Inc.
• Lombard Medical
• Translumina Gmbh
• Jotec Gmbh

Frequently Asked Questions (FAQs)